Latest News and Press Releases

SAN RAFAEL, Calif., Sept. 28, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that it has enrolled the first patient in a Phase 1/2 trial for BMN 270, an...

SAN RAFAEL, Calif., Sept. 18, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), today announced that it has entered into a settlement agreement with Dr. Reddy's Laboratories, Inc....

Morgan Stanley Global Healthcare Conference on September 16 in New York J.P. Morgan 6th Annual U.S. All Stars Conference on September 16 in London Bank of America Merrill Lynch Global...

SAN RAFAEL, Calif., Sept. 1, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced the introduction of kNOWyourDuchenne, a program to help families and physicians obtain...

Oral Presentations Include Long-Term Safety and Efficacy with Pegvaliase for Control of Blood Phenylalanine in Adults with PKU and a Review of the Ongoing Development Program for Reveglucosidase...

Talazoparib is a Highly-Potent PARP Inhibitor in Phase 3 Development for the Treatment of BRCA-Mutated Breast Cancer Clinical Activity Observed in Multiple Oncology Opportunities with...

SAN RAFAEL, Calif., Aug. 19, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that the U.S. Food and Drug Administration (FDA) has granted rare pediatric disease...

SAN RAFAEL, Calif., Aug. 19, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that it has been ranked 10th on Forbes magazine's 2015 list of the "World's Most...

- In First Six Months of 2015 Vimizim Sales Top $104 million and Total BioMarin Revenue Grows 32% Y/Y - First Patients Enrolled in 4th Cohort of Phase 2 Study of Vosoritide for the Treatment of...

SAN RAFAEL, Calif., July 27, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that it will become a component of the NASDAQ-100 Index® (NASDAQ:NDX), the...